Gamida Cell CEO To Present on ''Expanded Stem Cell Therapeutics: Status and Progress'' at the UBS Conference at the Grand Hyatt in NY, September 26, 2005.JERUSALEM -- Gamida Cell Ltd., announced today that Gamida Cell CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Yael Margolin will present on the topic of Expanded Stem Cell Therapeutics: Status and Progress, at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference, Monday, September 26, 2005 at 4:00 PM, at the Grand Hyatt in New York, NY. "Gamida Cell is at the forefront of the development of expanded stem cell therapeutics. It has been a busy and an exciting year, one which we believe will prove to be the precursor to even more great things to come. I look forward to briefing attendees on the status of our lead product, StemEx(R)," said Gamida Cell CEO Dr. Yael Margolin. Gamida Cell's Phase I/II study of StemEx(R) for the treatment of leukemia and lymphoma, which completed in January 2005, showed good safety. A pivotal study is scheduled to begin in the U.S., Europe and Israel in Q1 2006. In Q1 2005, Gamida Cell and Teva Pharmaceuticals established a joint venture to develop and market StemEx(R). The joint venture is funded with $25M from Teva and is equally owned and jointly managed by Gamida Cell and Teva. The market launch for StemEx(R) is anticipated for 2008. StemEx(R) was granted an orphan drug designation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in March 2005. Gamida Cell Ltd., (www.gamida-cell.com), is a leader in the expansion of hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. (blood) stem cell therapeutics in clinical development for cancer, as well as future regenerative cell-based medicines including cardiac and pancreatic diseases. The combined market potential of Gamida Cell's expanded stem cell products is estimated at $30 billion worldwide. Gamida Cell is currently pursuing partnerships and strategic alliances. Investors include Elscint (Europe-Israel), Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Investments, Denali Ventures, Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), NASDAQ: TEVA is an international pharmaceutical company headquartered in , Auriga Ventures, Pamot and Comsor. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion